Case Reports
doi: 10.1155/2010/171265.
Epub 2010 May 11.
Vitiligo after diphencyprone for alopecia areata
Affiliations
- PMID: 20585597
- PMCID: PMC2879911
- DOI: 10.1155/2010/171265
Item in Clipboard
Case Reports
Vitiligo after diphencyprone for alopecia areata
Dermatol Res Pract.
2010.
Abstract
The topical immunotherapy is used to treat alopecia areata and recalcitrant warts since the 1970s. Diphencyprone is a contact sensitizer used to treat dermatological conditions resulting from as altered immunological state, such as extensive alopecia areata, being partially effective and safe. Side effects include local eczema with blistering, regional lymphadenopathy and contact urticaria. Rare adverse effects include an erythema multiforme-like reaction, hyperpigmenttion, hypopigmentation, and vitiligo. We report a 30-year-old, Brazilian male who developed vitiligo lesions following DPCP therapy for alopecia areata.
Similar articles
-
Diphencyprone induced vitiligo: a case report.Case Rep Med. 2012;2012:356236. doi: 10.1155/2012/356236. Epub 2012 Jul 1. Case Rep Med. 2012. PMID: 22811720 Free PMC article.
-
Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.BMC Dermatol. 2005 May 26;5:6. doi: 10.1186/1471-5945-5-6. BMC Dermatol. 2005. PMID: 15918897 Free PMC article. Clinical Trial.
-
Topical immunotherapy in dermatology.Int J Clin Pract. 1999 Mar;53(2):130-7. Int J Clin Pract. 1999. PMID: 10344049 Review.
-
Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA).Eur Ann Allergy Clin Immunol. 2003 Dec;35(10):397-401. Eur Ann Allergy Clin Immunol. 2003. PMID: 14768526 Clinical Trial.
-
Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata.Dermatol Ther (Heidelb). 2022 Nov;12(11):2415-2452. doi: 10.1007/s13555-022-00818-7. Epub 2022 Sep 22. Dermatol Ther (Heidelb). 2022. PMID: 36136235 Free PMC article. Review.
Cited by
-
Depigmentation Following Diphenylcyclopropenone Immunotherapy Leading to Discontinuation of Treatment.Int J Trichology. 2022 Jul-Aug;14(4):144-146. doi: 10.4103/ijt.ijt_75_20. Epub 2022 Jul 16. Int J Trichology. 2022. PMID: 36081437 Free PMC article. No abstract available.
-
Diphenylcyclopropenone-induced vitiligo in a patient with alopecia universalis.Case Rep Dermatol. 2013 Aug 17;5(2):225-31. doi: 10.1159/000354767. eCollection 2013. Case Rep Dermatol. 2013. PMID: 24019775 Free PMC article.
-
Diphencyprone induced vitiligo: a case report.Case Rep Med. 2012;2012:356236. doi: 10.1155/2012/356236. Epub 2012 Jul 1. Case Rep Med. 2012. PMID: 22811720 Free PMC article.
-
Squalene-containing nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of diphencyprone for treating alopecia areata.Pharm Res. 2013 Feb;30(2):435-46. doi: 10.1007/s11095-012-0888-0. Epub 2012 Oct 16. Pharm Res. 2013. PMID: 23070602
-
Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens.Postepy Dermatol Alergol. 2018 Dec;35(6):577-581. doi: 10.5114/ada.2018.77608. Epub 2018 Nov 8. Postepy Dermatol Alergol. 2018. PMID: 30618524 Free PMC article.
References
-
- Sittart JAS, Pires MC. Discromias. In: Roca AR, editor. Dermatologia na Prática Médica. São Paulo, Brazil: 2007. pp. 351–368.
-
- Daman LA, Rosenberg EW, Drake L. Treatment of alopecia areata with dinitrochlorobenzene. Archives of Dermatology. 1978;114(7):1036–1038. - PubMed
-
- Happle R, Cebulla K, Echternacht-Happle K. Dinitrochlorobenzene therapy for alopecia areata. Archives of Dermatology. 1978;114(11):1629–1631. - PubMed
-
- Warin AP. Dinitrochlorobenzene in alopecia areata. Lancet. 1979;1(8122):p. 927. - PubMed
-
- Mohan K, Balachandran C, Shenoi S, Rao R, Sripathi H, Prabhu S. Topical dinitrochlorobenzene (DNCB) for alopecia areata: revisited. Indian Journal of Dermatology, Venereology and Leprology. 2008;74(4):401–402. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
